BioSpaceOriginal article
Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints
Phase 3negativeNegative
AI Analysis
Summary
Novartis' $12 billion Avidity acquisition faces a setback as the company's antibody-oligonucleotide conjugate failed to meet its primary endpoint of significantly improving hand function in myotonic dystrophy type 1 patients, though secondary measures showed some clinical activity.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Failed to significantly improve hand function in patients with myotonic dystrophy type 1; showed signs of clinical activity in secondary and exploratory measures
Importance:7/10
Sentiment:
-0.60
Phase 3 failureacquisitionmyotonic dystrophyantibody-oligonucleotide conjugate
Read the original article
Published by BioSpace on September 8, 2026 12:05 PM